Drug class | Drug | Study | Sponsor | Population | Region | Study duration | Primary outcome/endpoint |
---|---|---|---|---|---|---|---|
CD 80/86 inhibitor | abatacept | Limit-JIA, NCT03841357 | Duke University | OJIA | United States | 10/2019–12/2022 | Joint count, active anterior uveitis |
IL-23 inhibitor | guselkumab | aPROTOSTAR, NCT03451851 | Janssen | Paediatric psoriasis | global | 7/2018–6/2025 | PASI75, PGA ≤1 |
risankizumab | bM19–977, NCT04435600 | Abbvie | Paediatric psoriasis | United States | 7/2020–06/2025 | PASI75; PGA ≤ 1 | |
tildrakizumab | TILD-19-12, NCT03997786 | Sun Pharma Global FZE | Paediatric psoriasis | United States | 1/2020–11/2023 | PASI75, PGA ≤1 | |
IL-17 inhibitor | brodalumab | cEMBRACE 1, NCT04305327 | LEO Pharma | Paediatric psoriasis | global | 9/2020–11/2023 | PASI75 |
secukinumab | dCAIN457F2304, NCT03031782 | Novartis | PsA, ERA | global | 5/2017–12/2020 | Disease flare | |
eCAIN457A2311, NCT03668613 | Novartis | Paediatric psoriasis | global | 8/2018–9/2023 | PASI75, PGA ≤1 | ||
fCAIN457A2310, NCT02471144 | Novartis | Paediatric psoriasis | global | 9/2015–7/2023 | PASI75, PGA ≤1 | ||
TNF inhibitor | adalimumab | gADJUST, NCT03816397 | UCSF | JIA-associated uveitis | United States | 12/2019–12/2022 | Treatment failure |
etanercept | STARS, EudraCT 2018–001931-27 | IRCCS Istituto Giannina Gaslini | OJIA, PJIA | Italy | NA | Clinical inactive disease | |
infliximab | KIDCARE, NCT03065244 | UCSD | Kawasaki disease | United States | 2/2017–9/2020 | Fever | |
certolizumab pegol | CIMcare, NCT04123795 | UCB Biopharma | Paediatric psoriasis | North America | 1/2020–4/2023 | PASI75, PGA ≤1 | |
JAK inhibitor | baricitinib | hJUVE-BRIGHT, NCT04088409 | Eli Lilly | JIA-associated uveitis | Europe | 10/2019–7/2022 | Uveitis disease response |
iJUVE-BALM, NCT04088396 | Eli Lilly | SJIA | global | 2/2020–4/2023 | Disease flare | ||
jJUVE-BASIS, NCT03773978 | Eli Lilly | PJIA, extended OJIA, ERA, PsA | global | 12/2018–8/2021 | Disease flare | ||
tofacitinib | A3921165, NCT03000439 | Pfizer | SJIA | global | 5/2018–8/2023 | Disease flare |